Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study

Robert Flisiak; Joanna Pogorzelska; Hanna Berak; Andrzej Horban; Iwona Orłowska; Krzysztof Simon; Ewelina Tuchendler; Grzegorz Madej; Anna Piekarska; Maciej Jabłkowski; Zbigniew Deroń; Włodzimierz Mazur; Marcin Kaczmarczyk; Ewa Janczewska; Arkadiusz Pisula; Jacek Smykał; Krzysztof Nowak; Marek Matukiewicz; Waldemar Halota; Joanna Wernik; Katarzyna Sikorska; Iwona Mozer-Lisewska; Błażej Rozpłochowski; Aleksander Garlicki; Krzysztof Tomasiewicz; Joanna Krzowska-Firych; Barbara Baka-Ćwierz; Wiesław Kryczka; Dorota Zarębska-Michaluk; Iwona Olszok; Anna Boroń-Kaczmarska; Barbara Sobala-Szczygieł; Bronisława Szlauer; Bogumiła Korcz-Ondrzejek; Jerzy Sieklucki; Robert Pleśniak; Agata Ruszała; Barbara Postawa-Kłosińska; Jolanta Citko; Anna Lachowicz-Wawrzyniak; Joanna Musialik; Edyta Jezierska; Witold Dobracki; Beata Dobracka; Jan Hałubiec; Rafał Krygier; Anna Strokowska; Wojciech Chomczyk; Krystyna Witczak-Malinowska

doi:10.5114/ceh.2016.63870

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2016
vol. 2

Send email

Copy url:

abstract:

Original paper

Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study

Robert Flisiak

,

Joanna Pogorzelska

,

Hanna Berak

,

Andrzej Horban

,

Iwona Orłowska

,

Krzysztof Simon

,

Ewelina Tuchendler

,

Grzegorz Madej

,

Anna Piekarska

,

Maciej Jabłkowski

,

Zbigniew Deroń

,

Włodzimierz Mazur

,

Marcin Kaczmarczyk

,

Ewa Janczewska

,

Arkadiusz Pisula

,

Jacek Smykał

,

Krzysztof Nowak

,

Marek Matukiewicz

,

Waldemar Halota

,

Joanna Wernik

,

Katarzyna Sikorska

,

Iwona Mozer-Lisewska

,

Błażej Rozpłochowski

,

Aleksander Garlicki

,

Krzysztof Tomasiewicz

,

Joanna Krzowska-Firych

,

Barbara Baka-Ćwierz

,

Wiesław Kryczka

,

Dorota Zarębska-Michaluk

,

Iwona Olszok

,

Anna Boroń-Kaczmarska

,

Barbara Sobala-Szczygieł

,

Bronisława Szlauer

,

Bogumiła Korcz-Ondrzejek

,

Jerzy Sieklucki

,

Robert Pleśniak

,

Agata Ruszała

,

Barbara Postawa-Kłosińska

,

Jolanta Citko

,

Anna Lachowicz-Wawrzyniak

,

Joanna Musialik

,

Edyta Jezierska

,

Witold Dobracki

,

Beata Dobracka

,

Jan Hałubiec

,

Rafał Krygier

,

Anna Strokowska

,

Wojciech Chomczyk

,

Krystyna Witczak-Malinowska

Clin Exp HEPATOL 2016; 2, 4: 138–143

DOI: https://doi.org/10.5114/ceh.2016.63870

Online publish date: 2016/11/28

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Flisiak R, Pogorzelska J, Berak H, et al. Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study. Clinical and Experimental Hepatology. 2016;2(4):138-143. doi:10.5114/ceh.2016.63870.

APA

Flisiak, R., Pogorzelska, J., Berak, H., Horban, A., Orłowska, I.,  & Simon, K. et al. (2016). Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study. Clinical and Experimental Hepatology, 2(4), 138-143. https://doi.org/10.5114/ceh.2016.63870

Chicago

Flisiak, Robert, Joanna Pogorzelska, Hanna Berak, Andrzej Horban, Iwona Orłowska, Krzysztof Simon,  and Ewelina Tuchendler et al. 2016. "Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study". Clinical and Experimental Hepatology 2 (4): 138-143. doi:10.5114/ceh.2016.63870.

Harvard

Flisiak, R., Pogorzelska, J., Berak, H., Horban, A., Orłowska, I., Simon, K., Tuchendler, E., Madej, G., Piekarska, A., Jabłkowski, M., Deroń, Z., Mazur, W., Kaczmarczyk, M., Janczewska, E., Pisula, A., Smykał, J., Nowak, K., Matukiewicz, M., Halota, W., Wernik, J., Sikorska, K., Mozer-Lisewska, I., Rozpłochowski, B., Garlicki, A., Tomasiewicz, K., Krzowska-Firych, J., Baka-Ćwierz, B., Kryczka, W., Zarębska-Michaluk, D., Olszok, I., Boroń-Kaczmarska, A., Sobala-Szczygieł, B., Szlauer, B., Korcz-Ondrzejek, B., Sieklucki, J., Pleśniak, R., Ruszała, A., Postawa-Kłosińska, B., Citko, J., Lachowicz-Wawrzyniak, A., Musialik, J., Jezierska, E., Dobracki, W., Dobracka, B., Hałubiec, J., Krygier, R., Strokowska, A., Chomczyk, W.,  and Witczak-Malinowska, K. (2016). Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study. Clinical and Experimental Hepatology, 2(4), pp.138-143. https://doi.org/10.5114/ceh.2016.63870

MLA

Flisiak, Robert et al. "Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study." Clinical and Experimental Hepatology, vol. 2, no. 4, 2016, pp. 138-143. doi:10.5114/ceh.2016.63870.

Vancouver

Flisiak R, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K et al. Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study. Clinical and Experimental Hepatology. 2016;2(4):138-143. doi:10.5114/ceh.2016.63870.

PlumX metrics:

The aim of the study was to analyze the efficacy achieved with regimens available for chronic hepatitis C (CHC) in Poland between 2013 and 2016.

Material and methods: Data were collected from 29 centers and included 6786 patients with available sustained virologic response (SVR) data between 1 January 2013 and 31 March 2016.

Results: The sustained virologic response rate for genotypes (G) 1a, 1b, 2, 3 and 4 was 62%, 56%, 92%, 67% and 56% respectively; 71% patients (n = 4832) were treated with pegylated interferon  (Peg-IFN) and ribavirin (RBV), with SVR rates of 58%, 49%, 92%, 67% and 55% respectively. The sustained virologic response among 5646 G1 infected patients was the lowest with natural interferon  (7%, n = 70) or PegIFN (50%, n = 3779) with RBV, and improved in those receiving triple regimens of Peg-IFN + RBV combined with boceprevir (47%, n = 485), telaprevir (64%, n = 805), simeprevir (73%, n = 132) or sofosbuvir (70%, n = 23). The sustained virologic response with interferon-free regimens of sofosbuvir and RBV (n = 7), sofosbuvir and simeprevir (n = 53), and ledipasvir and sofosbuvir (n = 64) achieved 86%, 89% and 94% respectively. The highest SVR of 98% was observed with ombitasvir/paritaprevir combined with dasabuvir (n = 227). Patients infected with G3 (n = 896) and G4 (n = 220) received mostly Peg-IFN + RBV with SVR of 67% and 56% respectively. Interferon-free regimens were administered in 18 G3/G4 patients and all achieved an SVR. Sofosbuvir combined with Peg-IFN and RBV was administered to 33 patients with an SVR rate of 94%, and a similar rate was achieved among 13 G2 patients treated with interferon and RBV.

Conclusions: We observed significant differences in efficacy of HCV regimens available in Poland at the turn of the interferon era. The data will be useful as a comparison for therapeutic options expected in the next few years.

keywords:

Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study

liver, hepatitis C, therapy